Palantir Technologies Inc. (NASDAQ: PLTR) stock was up over 5% in intraday trading on Monday, March 2. The rally was caused by the initiation of military action by the United States and Israel ...
Equillium (EQ) remains a 'Hold' as it advances EQ504 for ulcerative colitis, with phase 1 trial initiation targeted for mid-2026. Company's Multi-Cytokine Platform enables selective cytokine targeting ...
Lynk Pharmaceuticals Co., Ltd. ('Lynk Pharmaceuticals'), a clinical-stage innovative drug development company focused on ...
6d
Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Q4 2025 net product revenue for ZORYVE® (roflumilast) was $127.5 million, an 84% increase compared to Q4 2024, and a 29% increase compared to Q3 ...
Biohaven Ltd. (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range ...
Immunocore reports fourth quarter and full year 2025 financial results and provides a business update KIMMTRAK (tebentafusp-tebn) Q4 net sales ...
Q4 2025 Earnings Call February 26, 2026 8:30 AM ESTCompany ParticipantsKate Rausch - Head of Investor RelationsPaul Bolno ...
Q4 2025 net product revenue for ZORYVE (roflumilast) was $127.5 million, an 84% increase compared to Q4 2024, and a 29% increase compared to Q3 2025Full year 2025 net product revenue for ZORYVE was ...
Chipps said “We’ve got two guys who would like to come on your framebuilding course. One has tool skills, the other has none at all. The contrast would make an interesting article.” Bill had served a ...
Corporate defendants are “operating in a new era of enhanced class action risks,” according to global law firm Duane Morris.
Jurors in Multnomah County Circuit Court on Wednesday awarded an eye-popping $305 million in damages to 16 plaintiffs in an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results